CAR-T细胞的作用机制及其在B淋巴细胞肿瘤治疗中的研究进展  

The Mechanism of CAR-T Cell and Its Progress in the Treatment of B Lymphocyte Tumor

作　　者：李晓清 杜新[1] 刘焕勋[1] 陈伟红[1] 古庆利[1] 胡春宏[2] LI Xiao- qing;DUXin;LIU Huan- xun;CHEN Wei- hong;GU Qing- li;HU Chun- hong(Shenzhen Second People＇s Hospital, Shenzhen 518000, China)

机构地区：[1]深圳市第二人民医院肿瘤内科,广东深圳518000 [2]中南大学附属湘雅二医院肿瘤内科,湖南长沙410000

出　　处：《标记免疫分析与临床》2018年第6期918-920,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)用于恶性肿瘤靶向治疗,在近几年已得到了飞速发展。经过基因改造的CAR-T细胞兼具CD19抗体基因和T细胞受体基因,可以特异性识别血液恶性肿瘤中B细胞所表达的特异性抗原CD19。将其回输给患者用以进行恶性肿瘤的治疗时,在CD19抗原刺激下,CAR-T细胞能够持续增殖活化,起到杀伤肿瘤细胞的作用,但此种治疗方式也有引起多种不良反应的风险。本文就上述问题及其在B淋巴细胞肿瘤的临床治疗作用进行初步综述。Chimericantigenreceptor T cell （CAR-T）is a new targeted therapy for malignant tumor and has been rapid developedin recent years. CAR-T cells genetically engineeredwith CD19 antibodies and T cell receptor genes can specifically identifyantigen CD19 expressed by the B cells in blood malignant tumor. When transferring backto patients by intravenous infusion pathway for the treatment of malignant tumor, under the stimulus of CD19 antigen, CAR-T cells can be activated, sustainably proliferate and have the effect of killing tumor cells. But this hasalso caused a variety of treatment risk of adverse reactions. In this paper, the problems and the effect of B lymphocyte tumor in clinical treatment will be preliminary reviewed.

关 键 词：CAR-T 白血病 靶向治疗 B细胞淋巴瘤 免疫 

分 类 号：R733.71[医药卫生—肿瘤]